ArticleAlzheimer's & dementia (New York, N. Y.)

Functional connectome metrics reveal distinct prognostic subtypes in two Phase 3 gantenerumab trials.

Susanna Gobbi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.